Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Rigel Pharmaceuticals Q2 EPS $3.28 Beats $0.19 Estimate, Sales $101.685M Beat $48.142M Estimate

Author: Benzinga Newsdesk | August 05, 2025 03:11pm
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly earnings of $3.28 per share which beat the analyst consensus estimate of $0.19 by 1626.32 percent. This is a 5566.67 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $101.685 million which beat the analyst consensus estimate of $48.142 million by 111.22 percent. This is a 176.01 percent increase over sales of $36.841 million the same period last year.

Posted In: RIGL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist